

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2026 Company Presentations

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name Lumenis Vision * Website Lumenis.com *

CEO name Liz Risenberg – AVP head of Vision Business Select a CATEGORY: Biotech/Pharma
or Medical Devices or Health IT/Digital or Bio Food or Bio Convergence or Service Providers *

(Delete categories you are not selecting)

Select one SESSION per abstract from the list below *

“Restoring Vision: Where Biology Meets Engineering.”

You may delete the section instructions, leaving only the bolded bullet title
Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational:** *Lumenis is a leading energy-based medical device company with over 60 years of innovation, delivering pioneering technologies for glaucoma, retina, and dry eye disease—from inventing photocoagulators and SLT to IPL for dry eye disease. Its minimally invasive solutions address a large, growing vision-care market, supported by global clinical partnerships, strong commercialization, and experienced medical device leadership.*
- **Core Technology:** *Lumenis’ latest innovations include OptiLIGHT, the first and only IPL FDA approved for dry eyes, targeting inflammation and meibomian gland dysfunction. And OptiLIFT, a dynamic muscle stimulation technology for addressing lower lid laxity and incomplete blinking. Both technologies address key root causes of Ocular Surface Disease – inflammation and the lid function, in a non-invasive, safe method.*
- **Product Profile/Pipeline:** *Lumenis is expanding its Dry Eye Disease (DED) segment through OptiLIGHT adoption and new solutions like OptiLIFT, driving. In parallel, it continues to invest in core glaucoma and retina markets, supported by innovations like the Digital Duet platform.*
- **Business Strategy:** *Lumenis is expanding its Dry Eye Disease (DED) segment through OptiLIGHT adoption and new solutions like OptiLIFT, driving. In parallel, it continues to invest in core glaucoma and retina markets, supported by innovations like the Digital Duet platform.*
- **What's Next?** *Continue to advance its technologies through ongoing research and development while supporting broader adoption across markets. The company remains focused on growth, strengthening its global footprint, and investing in innovation to support long-term value creation.*